Non-selective Beta-blocker in Compensated Advanced Chronic Liver Disease

PHASE4RecruitingINTERVENTIONAL
Enrollment

474

Participants

Timeline

Start Date

July 17, 2024

Primary Completion Date

July 30, 2031

Study Completion Date

July 30, 2031

Conditions
Portal HypertensionHepatic DecompensationAdvanced Chronic Liver Disease
Interventions
DRUG

Carvedilol

Patients in the NSBB arm will receive generic carvedilol. The starting dose of oral carvedilol is 6.25mg daily (to be taken once or twice per day) and can be adjusted at each scheduled visit (either by increasing the dosage or frequency of dose administration) according to patients' tolerance, as well as the blood pressure and pulse rate that the systolic blood pressure should be not lower than 90 mmHg and pulse rate not lower than 55 beats per minute. The dosage of carvedilol can also be titrated or discontinued at unscheduled visit according to patient's condition. In case carvedilol is discontinued, it can be resumed from the starting dose at next scheduled visit if there is no contraindication for carvedilol. The dose of carvedilol will be kept at 6.25-12.5mg per day unless there are additional non-hepatic indications such as arterial hypertension or cardiac disease warranting higher carvedilol dosage. The maximum allowed dose of carvedilol is 50mg daily as per drug instruction.

Trial Locations (1)

Unknown

RECRUITING

Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong

All Listed Sponsors
collaborator

Singapore General Hospital

OTHER

collaborator

University of Palermo

OTHER

collaborator

University of Malaya

OTHER

collaborator

Shanghai Jiao Tong University School of Medicine

OTHER

collaborator

Royal Prince Alfred Hospital, Sydney, Australia

OTHER

lead

Chinese University of Hong Kong

OTHER